Moderate

Non-Hodgkin lymphoma - management overview

NHL · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A heterogeneous group of lymphoid malignancies ranging from indolent (e.g. follicular) to aggressive (e.g. diffuse large B-cell). Management is subtype-specific; aggressive forms are potentially curable while many indolent ones are treated for control.

Red flags

  • Spinal cord compression or CNS involvement
  • SVC obstruction / airway compromise
  • Tumour lysis syndrome
  • Rapidly enlarging mass (transformation)
  • B symptoms with rapid deterioration

Assessment

Differential diagnosis

  • Hodgkin lymphoma
  • Reactive/infective lymphadenopathy
  • Chronic lymphocytic leukaemia
  • Metastatic carcinoma
  • Autoimmune lymphadenopathy
  • Plasma cell neoplasm

Investigations

  • Excisional/core lymph node biopsy with immunophenotyping and molecular studies
  • FBC, LDH, renal and liver function, urate
  • HIV and hepatitis B/C serology (reactivation risk with rituximab)
  • PET-CT and/or CT for staging
  • Bone marrow biopsy where indicated
  • Cardiac assessment before anthracyclines

Management

  • Obtain adequate tissue and precise histological subtyping
  • Stage with imaging and assess performance status and prognostic index (e.g. IPI/FLIPI)
  • Classify as aggressive or indolent to set treatment goals (cure vs control)
  • Screen hepatitis B before rituximab and give antiviral prophylaxis if positive
  • Treat diffuse large B-cell lymphoma with R-CHOP immunochemotherapy aiming for cure
  • Give tumour lysis prophylaxis in bulky/aggressive disease
  • Manage indolent follicular lymphoma with watch-and-wait if asymptomatic, or rituximab-based therapy when treatment indicated
  • Use CNS prophylaxis in high-risk aggressive lymphoma
  • Treat relapsed/refractory aggressive disease with salvage chemotherapy, autologous transplant, bispecific antibodies or CAR-T
  • Provide maintenance, surveillance and survivorship care per subtype

Drugs & doses

R-CHOP: rituximab 375 mg/m2 + cyclophosphamide 750 mg/m2 + doxorubicin 50 mg/m2 + vincristine 1.4 mg/m2 (cap 2 mg) IV day 1 + prednisolone 100 mg PO days 1-5, every 21 days
Bendamustine 90 mg/m2 IV days 1-2 + rituximab (indolent lymphoma)
Rituximab maintenance 375 mg/m2 every 2-3 months (follicular lymphoma)
Allopurinol/rasburicase for tumour lysis prophylaxis

Disposition

Haematology/oncology management; urgent admission for oncological emergencies; subtype-specific long-term follow-up.

Complications & pitfalls

  • Tumour lysis syndrome
  • Hepatitis B reactivation
  • Anthracycline cardiotoxicity
  • Transformation of indolent to aggressive lymphoma
  • Immunosuppression/infection
  • Relapse

Exam pearls

  • Precise subtyping dictates whether the aim is cure or disease control
  • Screen and cover hepatitis B before rituximab
  • Asymptomatic indolent lymphoma can be safely observed
  • CAR-T and bispecific antibodies are changing relapsed aggressive lymphoma outcomes
  • Rising LDH and rapid growth suggest aggressive or transformed disease

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.